Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + carboplatin + pemetrexed
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Atezolizumab + carboplatin + pemetrexed is a combination regimen used primarily as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors, thereby enhancing T-cell mediated immune responses against tumor cells. Carboplatin is a platinum-based chemotherapy agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. Pemetrexed is an antifolate chemotherapeutic that inhibits multiple folate-dependent enzymes involved in the synthesis of nucleotides, leading to inhibition of DNA and RNA synthesis in cancer cells. This combination leverages both immunotherapy (atezolizumab) and cytotoxic chemotherapy (carboplatin, pemetrexed) to improve outcomes in patients with advanced NSCLC.
- Brand names
- Tecentriq (for atezolizumab)Alimta (for pemetrexed)Pemfexy (for pemetrexed)
- Other names
- carboplatin + pemetrexed + atezolizumab
02
Targets
DHFR (Dihydrofolate reductase)DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)GART (GAR transformylase)
Beyond the preview
Go deeper on atezolizumab + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + carboplatin + pemetrexed.